Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?

References

1. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. 2002; Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 34:774–779 [CrossRef]
   [Google Scholar]
2. Arvin A. M, Gershon A. A. 1996; Live attenuated varicella vaccine. Annu Rev Microbiol 50:59–100 [CrossRef]
   [Google Scholar]
3. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S. 1994; Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 94:524–526
   [Google Scholar]
4. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, Coplan P, Sharrar R, Guess H. 1999; Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 18:1041–1046 [CrossRef]
   [Google Scholar]
5. Brisson M, Edmunds W. J. 2002; The cost-effectiveness of varicella vaccination in Canada. Vaccine 20:1113–1125 [CrossRef]
   [Google Scholar]
6. Brisson M, Edmunds W. J, Gay N. J, Law B, De Serres G. 2000; Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18:2775–2778 [CrossRef]
   [Google Scholar]
7. Brisson M, Gay N. J, Edmunds W. J, Andrews N. J. 2002; Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20:2500–2507 [CrossRef]
   [Google Scholar]
8. Clements D. A, Moreira S. P, Coplan P. M, Bland C. L, Walter E. B. 1999; Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 18:1047–1050 [CrossRef]
   [Google Scholar]
9. Edmunds W. J, Brisson M. 2002; The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 44:211–219 [CrossRef]
   [Google Scholar]
10. Garnett G. P, Grenfell B. T. 1992; The epidemiology of varicella-zoster virus infections: a mathematical model. Epidemiol Infect 108:495–511 [CrossRef]
    [Google Scholar]
11. Gershon A. A. 1995; Varicella-Zoster virus: prospects for control. Adv Pediatr Infect Dis 10:93–123
    [Google Scholar]
12. Gershon A. A, LaRussa P, Steinberg S, Mervish N, Lo S. H, Meier P. 1996; The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 173:450–453 [CrossRef]
    [Google Scholar]
13. Gray A. M, Fenn P, Weinberg J, Miller E, McGuire A. 1997; An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 119:209–220 [CrossRef]
    [Google Scholar]
14. Hardy I, Gershon A. A, Steinberg S. P, LaRussa P. 1991; The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 325:1545–1550 [CrossRef]
    [Google Scholar]
15. Johnson C. E, Stancin T, Fattlar D, Rome L. P, Kumar M. L. 1997; A long–term prospective study of varicella vaccine in healthy children. Pediatrics 100:761–766 [CrossRef]
    [Google Scholar]
16. Kappagoda C, Shaw P, Burgess M, Cramer L. 1999; Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health 35:341–345 [CrossRef]
    [Google Scholar]
17. Kuter B. J, Weibel R. E, Guess H. A. 7 other authors 1991; Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9:643–647 [CrossRef]
    [Google Scholar]
18. LaRussa P, Steinberg S, Gershon A. A. 1996; Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 174:SupplS320–S323 [CrossRef]
    [Google Scholar]
19. Oxman M. N. 1995; Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45:SupplS41–S46 [CrossRef]
    [Google Scholar]
20. ACIP 1999; Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 48 (RR-6):1–5
    [Google Scholar]
21. Seward J, Watson B. M, Peterson C. L. 9 other authors 2002; Varicella disease after introduction of varicella vaccine the United States 1995–2000. JAMA 287:606–611 [CrossRef]
    [Google Scholar]
22. Sharrar R. G, LaRussa P, Galea S. A, Steinberg S. P, Sweet A. R, Keatley R. M, Wells M. E, Stephenson W. P, Gershon A. A. 2000; The postmarketing safety profile of varicella vaccine. Vaccine 19:916–923 [CrossRef]
    [Google Scholar]
23. Varis T, Veskari T. 1996; Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174:S330–S334 [CrossRef]
    [Google Scholar]
24. Vazquez M, LaRussa P. S, Gershon A. A, Steinberg S. P, Freudigman K, Shapiro E. D. 2001; The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344:955–960 [CrossRef]
    [Google Scholar]
25. Weibel R. E, Neff B. J, J Kuter B. 7 other authors 1984; Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 310:1409–1411 [CrossRef]
    [Google Scholar]
26. White C. J, Kuter B. J, Hildebrand C. S. 7 other authors 1991; Varicella vaccine (VARIVAX) in healthy children and adolescents results from clinical trials; 1987 to 1989 Pediatrics 87:604–610
    [Google Scholar]